Rein Therapeutics (NASDAQ:RNTX) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Rein Therapeutics (NASDAQ:RNTX) to a sell rating in a research report report published on Saturday morning.

Other equities research analysts also recently issued research reports about the company. Citigroup downgraded Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Finally, downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.00.

Rein Therapeutics Price Performance

Shares of NASDAQ RNTX opened at $1.05 on Friday. Rein Therapeutics has a 1-year low of $1.00 and a 1-year high of $2.36. The business has a 50-day moving average of $1.37 and a 200-day moving average of $1.34. The company has a market capitalization of $29.44 million, a price-to-earnings ratio of -0.55 and a beta of 1.42.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30. Research analysts expect that Rein Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RNTX. Susquehanna International Group LLP acquired a new position in shares of Rein Therapeutics in the third quarter worth about $35,000. HRT Financial LP acquired a new position in shares of Rein Therapeutics in the fourth quarter worth about $38,000. Chicago Partners Investment Group LLC lifted its stake in shares of Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics in the second quarter worth about $68,000. Finally, Jane Street Group LLC acquired a new position in shares of Rein Therapeutics in the fourth quarter worth about $72,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.